In the preliminary injunction case, Sequenom said it sought to enjoin Ariosa Diagnostics from offering or selling its Harmony Prenatal Test, which is pending the ultimate resolution of the litigation between Ariosa Diagnostics and Sequenom.
Ariosa Diagnostics chief executive officer Ken Song said, "Ariosa Diagnostics has vigorously opposed Sequenom’s drastic attempt to bar Ariosa from competing with our Harmony Prenatal Test, and we feel pleased and vindicated by the Court’s order denying Sequenom’s preliminary injunction motion."
Ariosa Diagnostics is involved in providing safe prenatal tests for maternal and fetal health by using its proprietary technology to perform a directed analysis of cell-free DNA in blood.
